The short version of immunomodulatory peptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-11. Anything still debated is marked as such rather than presented as settled.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
=== Other types === Other types of chocolate are used in baking and confectionery. These include baking chocolate (often unsweetened), couverture chocolate (used for coating), compound chocolate (a lower-cost alternative) and modeling chocolate. Modeling chocolate is a chocolate paste made by melting chocolate and combining it with corn syrup, glucose syrup, or golden syrup.
By the 1820s, the different Nonconformists, including Wesleyan Methodists, Baptists, Congregationalists and Unitarians, had formed the Committee of Dissenting Deputies and agitated for repeal of the highly restrictive Test and Corporation Acts. These Acts excluded Nonconformists from holding civil or military office or attending Oxford or Cambridge, compelling them to set up their own Dissenting Academies privately. The Tories tended to be in favour of these Acts and so the Nonconformist cause was linked closely to the Whigs, who advocated civil and religious liberty. After the Test and Corporation Acts were repealed in 1828, all the Nonconformists elected to Parliament were Liberals. Nonconformists were angered by the Education Act 1902, which integrated Church of England denominational schools into the state system and provided for their support from taxes. John Clifford formed the National Passive Resistance Committee and by 1906 over 170 Nonconformists had gone to prison for refusing to pay school taxes. They included 60 Primitive Methodists, 48 Baptists, 40 Congregationalists and 15 Wesleyan Methodists. The political strength of Dissent faded sharply after 1920 with the secularisation of British society in the 20th century. The rise of the Labour Party reduced the Liberal Party strongholds into the nonconformist and remote "Celtic Fringe", where the party survived by an emphasis on localism and historic religious identity, thereby neutralising much of the class pressure on behalf of the Labour movement.
Despite protests against a plan to incinerate the hazardous waste in Pithampur, on January 1, 2025, an overnight caravan of a dozen semi trucks with police escort, a quick-response team, fire engines and ambulances delivered 377 tons of waste to Pithampur Industrial Area for incineration. Despite promises that the several hundred tons of toxic waste will be processed safely and responsibly, protests continued in Pithampur.
=== Multiple sclerosis symptoms === Spasticity. Based on the results of three high-quality trials and five of lower quality, oral cannabis extract was rated as effective, and THC as probably effective, for improving people's subjective experience of spasticity. Oral cannabis extract and THC both were rated as possibly effective for improving objective measures of spasticity. Nabiximols likely effectively reduces the severity of spasticity in the short‐term. Centrally mediated pain and painful spasms. Based on the results of four high-quality trials and four low-quality trials, oral cannabis extract was rated as effective, and THC as probably effective in treating central pain and painful spasms. Bladder dysfunction. Based on a single high quality study, oral cannabis extract and THC were rated as probably ineffective for controlling bladder complaints in multiple sclerosis.
Scott Tanner is a Canadian scientist, inventor, and entrepreneur. His areas of expertise include mass spectroscopy, especially inductively coupled plasma mass spectrometry (ICP-MS), and mass cytometry. Tanner is best known for his work on the fundamentals of inductively coupled plasma mass spectrometry, for the invention of mass cytometry, and co-founding (with Dmitry Bandura, Vladimir Baranov and Olga Ornatsky) DVS Sciences in 2004,(acquired by Fluidigm in 2014 and then renamed to Standard BioTools in 2022) the company that first commercialized the instrument and reagents of mass cytometry.
Sources: en.wikipedia.org
small/non-small cell lung cancer oesophageal cancer uterine cervical cancer urothelial cancer testicular cancer ovarian cancer prostate cancer head and neck cancer Nedaplatin is most often compared to other platinum-based drugs, most notably cisplatin. Many randomized controlled trials have been performed to compare nedaplatin and cisplatin, with uncertain results. One meta-analysis of 14 trials indicated no difference in efficacy in terms of median overall survival. Another meta-analysis of 17 trials looking specifically at concurrent chemoradiotherapy treatment for cervical cancer also found no difference in 3 year all-cause mortality, but did favour nedaplatin for 1 year all-cause mortality.
11 April – A study confirms antidepressant potential of psilocybin therapy protocols (which use the active ingredient in psilocybin mushrooms), providing fMRI data about a correlated likely major effect mechanism – global increases in brain network integration. 12 April – Science and the 2022 Russian invasion of Ukraine:An editorial in a scientific journal reports that relevant areas of food system research are patchy and lack independent assessments. An editorial projects significant gender and age imbalance in the population in Ukraine as a substantial problem if most refugees, as in other cases, do not return over time (4 Apr). A preprint reports impacts of the Ukrainian power grid synchronization with Continental Europe (15 Apr).
== Molecular weight distribution in linear polymerization == The product of a polymerization is a mixture of polymer molecules of different molecular weights. For theoretical and practical reasons, it is of interest to discuss the distribution of molecular weights in a polymerization. The molecular weight distribution (MWD) had been derived by Flory by a statistical approach based on the concept of equal reactivity of functional groups.
In total ten Venera probes achieved a soft landing on the surface of Venus. In 1984, the Soviet Vega programme began and ended with the launch of two crafts launched six days apart, Vega 1 and Vega 2. Both crafts deployed a balloon in addition to a lander, marking a first in spaceflight. The US never caught up or matched the Soviet efforts to explore the surface of Venus, but did claim the title of the first successful probe to have flown by the planet and had notable success with the Pioneer atmospheric probes.
Sources: en.wikipedia.org
== Toxicity == The short-term lethal dose of melamine is on a par with common table salt, with an LD50 of more than 3 grams per kilogram of bodyweight. U.S. Food and Drug Administration (FDA) scientists explained that when melamine and cyanuric acid are absorbed into the bloodstream, they concentrate and interact in the urine-filled renal tubules, then crystallize and form large numbers of round, yellow crystals, which in turn block and damage the renal cells that line the tubes, causing the kidneys to malfunction and lead to kidney stones, kidney failure, and death. Signs of melamine toxicity can include irritability, blood in the urine, little to no urine, symptoms of kidney infection, or high blood pressure. The European Union set a standard for acceptable human consumption (tolerable daily intake or TDI) of melamine at 0.2 mg per kilogram of body mass (previously 0.5 mg/kg), Canada declared a limit of 0.35 mg/kg, and the US FDA's limit was put at 0.063 mg/kg (previously 0.63 mg/kg). The World Health Organization's food safety director estimated that the amount of melamine a person could stand per day without incurring a bigger health risk, the TDI, was 0.2 mg per kilogram of body mass. Toxicity of melamine can be mediated by intestinal microbiota. In culture, Raoultella terrigena, which rarely colonizes mammalian intestines, was shown to convert melamine to cyanuric acid directly. Rats colonized by R. terrigena showed greater melamine-induced kidney damage compared to those not colonized.
Yet Bacillus subtilis inoculation may provide some benefit to growers by speeding corm growth and increasing stigma biomass yield. The plants fare poorly in shady conditions; they grow best in full sunlight. Fields that slope towards the sunlight are optimal (i.e., south-sloping in the Northern Hemisphere). Planting is mostly done in June in the Northern Hemisphere, where corms are lodged 7–15 cm (3–6 in) deep; its roots, stems, and leaves can develop between October and February. Planting depth and corm spacing, in concert with climate, are critical factors in determining yields. Mother corms planted deeper yield higher-quality saffron, though they form fewer flower buds and daughter corms. Italian growers optimise thread yield by planting 15 cm (6 in) deep and in rows 2–3 cm (3⁄4–1+1⁄4 in) apart; depths of 8–10 cm (3–4 in) optimise flower and corm production. Greek, Moroccan, and Spanish growers employ distinct depths and spacings that suit their locales. C. sativus prefers friable, loose, low-density, well-watered, and well-drained clay-calcareous soils with high organic content. Traditional raised beds promote good drainage. Soil organic content was historically boosted via application of some 20–30 tonnes per hectare (9–13 short tons per acre) of manure. Afterwards, and with no further manure application, corms were planted. After a period of dormancy through the summer, the corms send up their narrow leaves and begin to bud in early autumn. Only in mid-autumn do they flower.
Myrna Crenshaw Brown (July 6, 1959 – April 1, 2007), best known as Screechy Peach, was an American singer and songwriter. Initially the lead singer of Whild Peach, alongside her husband, guitarist David Whild, she would acquire fame in the 1990s due to her collaboration with such artists as Outkast and Macy Gray.
A money laundering offence under UK legislation need not even involve money, since the money laundering legislation covers assets of any description. In consequence, any person who commits an acquisitive crime (i.e., one that produces some benefit in the form of money or an asset of any description) in the UK inevitably also commits a money laundering offence under UK legislation. This applies also to a person who, by criminal conduct, evades a liability (such as a taxation liability)—which lawyers call "obtaining a pecuniary advantage"—as he is deemed thereby to obtain a sum of money equal in value to the liability evaded. The principal money laundering offences carry a maximum penalty of 14 years' imprisonment. Secondary regulation is provided by the Money Laundering Regulations 2003, which were replaced by the Money Laundering Regulations 2007. They are directly based on the EU Directives 91/308/EEC, 2001/97/EC and (through the 2007 regulations) 2005/60/EC. The regulations list a number of supervisory authorities who have a role in overseeing the financial activities of their members. One consequence of the Act is that solicitors, accountants, tax advisers, and insolvency practitioners who suspect (as a consequence of information received in the course of their work) that their clients (or others) have engaged in tax evasion or other criminal conduct that produced a benefit, now must report their suspicions to the authorities (since these entail suspicions of money laundering).
== Testing for HHV-6 == The table below presents a comprehensive overview of various diagnostic tests used to detect human herpesvirus 6 (HHV-6), detailing their ability to distinguish between active and latent infections. It also includes insights on the interpretation of test results, identifies providers that offer these tests, and indicates which methods are suitable for detecting HHV-6A in the endometrial lining—an important consideration for evaluating potential causes of infertility in women. The table serves as a guide for healthcare professionals to select appropriate diagnostic tests for HHV-6.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.